IRIS
TOCCHETTI, CARLO GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.382
EU - Europa 1.925
AS - Asia 677
AF - Africa 121
SA - Sud America 17
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.127
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.317
IT - Italia 981
CN - Cina 468
NL - Olanda 207
FI - Finlandia 136
DE - Germania 105
UA - Ucraina 101
SE - Svezia 98
IE - Irlanda 91
VN - Vietnam 87
CI - Costa d'Avorio 85
CA - Canada 61
FR - Francia 37
IN - India 37
GB - Regno Unito 31
ES - Italia 25
PT - Portogallo 20
JP - Giappone 18
BE - Belgio 17
BG - Bulgaria 15
SG - Singapore 14
NG - Nigeria 12
EG - Egitto 11
TR - Turchia 11
CO - Colombia 9
SK - Slovacchia (Repubblica Slovacca) 9
HK - Hong Kong 8
PL - Polonia 8
RU - Federazione Russa 7
GR - Grecia 6
KR - Corea 5
AR - Argentina 4
AT - Austria 4
GE - Georgia 4
HR - Croazia 4
MA - Marocco 4
MX - Messico 4
PH - Filippine 4
PK - Pakistan 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
IR - Iran 3
KE - Kenya 3
LT - Lituania 3
LV - Lettonia 3
MK - Macedonia 3
TW - Taiwan 3
AU - Australia 2
BJ - Benin 2
CH - Svizzera 2
CL - Cile 2
CY - Cipro 2
EU - Europa 2
IL - Israele 2
NO - Norvegia 2
RO - Romania 2
TN - Tunisia 2
AM - Armenia 1
BD - Bangladesh 1
BR - Brasile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
LI - Liechtenstein 1
NZ - Nuova Zelanda 1
OM - Oman 1
SI - Slovenia 1
TH - Thailandia 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 6.127
Salva come PNG Salva come JPEG
Città #
Chandler 779
Ashburn 256
Amsterdam 197
Millbury 187
Naples 175
Nanjing 152
Boston 148
Des Moines 136
Princeton 131
Wilmington 109
Jacksonville 100
Dong Ket 86
Lawrence 86
Beijing 81
Napoli 70
Ottawa 55
Woodbridge 54
Hebei 40
Nanchang 39
Rome 36
Shenyang 33
Pune 31
Milan 29
Houston 26
Seattle 26
Norwalk 23
Washington 21
Fairfield 20
Lappeenranta 20
Dearborn 19
Jiaxing 19
Palermo 18
Changsha 16
Redwood City 16
Tianjin 16
Boardman 15
Guangzhou 15
Sofia 15
Caserta 14
Council Bluffs 14
Dublin 14
Bologna 13
Chengdu 12
Rho 12
Turin 12
Augusta 11
Madrid 11
Menlo Park 11
Brescia 10
Fisciano 10
Kronberg 10
Los Angeles 10
Montijo 10
Perugia 10
Battipaglia 9
Hangzhou 9
Kosice 9
Maasmechelen 9
Ariano Irpino 8
Manfredonia 8
Marcianise 8
Singapore 8
Solofra 8
Cambridge 7
Shenzhen 7
Bari 6
Bogotá 6
Florence 6
Foggia 6
Kunming 6
Trieste 6
Catania 5
Cicciano 5
Hong Kong 5
Leawood 5
Mountain View 5
Shanghai 5
Stockholm 5
Warsaw 5
Ann Arbor 4
Bergamo 4
Cairo 4
Cologne 4
Düsseldorf 4
Fremont 4
Grottolella 4
Jinan 4
Locorotondo 4
Oeiras 4
Piemonte 4
San Mateo 4
Sarno 4
Tbilisi 4
Torino 4
Torre Annunziata 4
Zagreb 4
Ankara 3
Athens 3
Aydin 3
Brussels 3
Totale 3.725
Salva come PNG Salva come JPEG
Nome #
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice 479
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 85
Aldose Reductase Inhibition or Activation of Transketolase Offset Adverse Metabolic Remodeling Improving Function in Type 2 Diabetes Myocytes Exposed to Hyperglycemia 69
Antineoplastic drug-induced cardiotoxicity: A redox perspective 62
Late INa Inhibition with Ranolazine Blunts Doxorubicin- Induced Cardiac Dysfunction and Remodeling in Mice 60
Doxorubicin-induced cardiotoxicity in mice is blunted by late sodium current inhibition with ranolazine, with improvement in heart function, fibrosis and apoptosis. 59
Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed 59
Palmitate improves basal and beta-stimulated left ventricle function in diabetic mouse hearts 58
ANTHRACYCLINE INDUCED CARDIOTOXICITY IN MICE IS PREVENTED BY LATE INA INHIBITION WITH RANOLAZINE, WITH IMPROVEMENT IN HEART FUNCTION, FIBROSIS, APOPTOSIS 56
Cardiac sympathetic dysfunction in pulmonary arterial hypertension: Lesson from left-sided heart failure 56
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production 54
Utility of 2D-speckle tracking echocardiography in early identification of left ventricular dysfunction in antineoplastic therapy-induced cardiotoxicity. 53
Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. 53
Meccanismi molecolari della cardiotossicità indotta da antracicline e radioterapia 53
Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities 53
Toward standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function 50
Effect of inhibition of ErbB2-tyrosine kinase domain with lapatinib on cardiac dysfunction compared to the antibody trastuzumab in mice 49
Palmitate Improves Redox Balance and Enhances Contractility While Offsetting Adverse Effects of Hyperglycemia in the Diabetic Cardiomyocyte 49
Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients 49
Palmitate re-directs glucose utilization in type 2 diabetic hearts, improving function: a metabolomic/fluxomic study. 48
Severe Aortic Valve Regurgitation in Relapsing Polychondritis 48
Cardiac overexpression of CK improves myocellular function in murine heart failure. 47
The anticancer mTOR-inhibitor temsirolimus induces cardiac dysfunction in mice 47
Mitral peak early diastolic filling velocity to deceleration time ratio as a predictor of prognosis in patients with chronic heart failure and preserved or reduced ejection fraction. 47
Permanent atrial fibrillation and pulmonary embolism in elderly patients without deep vein thrombosis: is there a relationship? 46
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue 46
What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients 45
Targeting fibrosis in the failing heart with nanoparticles. 44
The Tyrosine Kinase ErbB2 Inhibitor Lapatinib and the Anti- ErbB2 Antibody Trastuzumab Depress Cardiac Function Without Inducing Left Ventricular Dilation in Mice 43
The Influence of Fiber on Gut Microbiota: Butyrate as Molecular Player Involved in the Beneficial Interplay Between Dietary Fiber and Cardiovascular Health 43
Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF): lupus in fabula? 43
Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart 43
Nitroxyl: A positive inotrope enhancing SR CA(2+) cycling in isolated myocytes 42
Biomarkers in sarcopenia: A multifactorial approach. 42
Dobutamine stress echocardiography in hypertrophic cardiomyopathy 41
Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. 41
Cardiotoxicity of immune checkpoint inhibitors 41
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 41
Abnormal glucose transport and GLUT1 cell-surface content in fibroblasts and skeletal muscle from NIDDM and obese subjects 40
The innate immune system in chronic cardiomyopathy: A European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC 40
Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients 40
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology – Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications 40
Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right-Sided Heart Failure and Tricuspid Regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC 39
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study 39
Prognostic Significance of Left Atrial Volume Dilatation in Patients with Hypertrophic Cardiomyopathy 39
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond 39
Hemodynamic effects of isometric exercise in hypertrophic cardiomyopathy: comparison with normal subjects 38
Physical vs. multidimensional frailty in older adults with and without heart failure 38
Time-weighted lactate as a predictor of adverse outcome in acute heart failure 38
A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial 37
Adapted recreational football Small Sided Games improves cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes: results from a pilot study 37
Non-coding RNAs - Update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart 37
Bmi1 inhibitor PTC-209 promotes Chemically-induced Direct Cardiac Reprogramming of cardiac fibroblasts into cardiomyocytes 37
Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart 37
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 37
Myocardial collagen turnover in hypertrophic cardiomyopathy 36
Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs 36
The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology 36
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth 36
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 36
Bidirectional cross-regulation between ErbB2 and β-adrenergic signaling pathways 35
Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology 35
Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases 35
DECREASED GLOBAL LONGITUDINAL STRAIN WITH MYOCARDITIS FROM IMMUNE CHECKPOINT INHIBITORS AND OCCURRENCE OF MAJOR ADVERSE CARDIAC EVENTS 35
The continuous heart failure spectrum: moving beyond an ejection fraction classification 35
Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens 35
Tetrahydrobiopterin (BH4) reverses established heart failure normalizing calcium cycling at the cardiomyocytes level 34
Direct oral anticoagulants across the heart failure spectrum: the precision medicine era 34
An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology 34
Oxidative stress in anticancer therapies-related cardiac dysfunction 34
Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions—A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology 33
Editorial: Novel Therapeutic Strategies for the Treatment of Chronic Diseases 33
'Circulating' RNA-based therapies in Cardio-Oncology 32
Metabolic Aspects of Anthracycline Cardiotoxicity 32
Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications 32
Common Mechanistic Pathways in Cancer and Heart Failure 32
Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis 31
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs 31
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors 31
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. 30
The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) 30
Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC) 30
Reciprocal organ interactions during heart failure-a position paper from the ESC working group on myocardial function 30
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF 30
A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases 30
Pathophysiology of anthracycline cardiotoxicity 29
DOXORUBICIN-INDUCED CARDIOTOXICITY IN MICE IS PREVENTED BY LATE INA INHIBITION WITH RANOLAZINE, WITH IMPROVEMENT IN HEART FUNCTION, FIBROSIS AND APOPTOSIS 29
Complex Roads from Genotype to Phenotype in Dilated Cardiomyopathy: Scientific update from the Working Group of Myocardial Function of the European Society of Cardiology 29
New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management 29
Le alterazioni elettrocardiografiche espressione di cardiotossicita’ (Electrocardiographic changes: expression of cardiotoxicity) 28
Inhibition of cardiomyocytes late INa with ranolazine to prevent anthracyclines cardiotoxicity in experimental models in vitro and in vivo 28
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology 28
Beta-blockers in pulmonary arterial hypertension: Time for a second thought? 28
Cardiac Remodelling Part 1: From Cells and Tissues to Circulating Biomarkers 28
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology 28
PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus 27
Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5 27
The activation of metabolites of nitric oxide synthase by metals is both redox and oxygen dependent: A new feature of nitrogen oxide signaling 27
Protective mechanisms of mitochondria and heart function in diabetes. 27
Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models 27
Totale 4.408
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.028
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.028
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201963 0 0 0 0 0 0 0 0 0 0 13 50
2019/2020666 270 8 31 24 47 25 22 33 17 45 81 63
2020/2021625 26 57 42 39 48 65 52 31 46 60 63 96
2021/20221.132 31 4 15 21 30 32 42 62 101 100 190 504
2022/20232.192 251 122 84 176 273 209 58 258 381 240 105 35
2023/20241.239 47 190 230 115 89 216 72 184 29 48 19 0
Totale 6.617